Outcomes With Radium-223 Therapy In Clinical Practice Of Metastatic Castration Resistant Prostate Cancer (Mcrpc).

e16073 Background: Radium-223 use in clinical practice is challenged by paucity of data on biomarkers and optimal sequencing of radium-223 with other therapies. We sought to identify potential variables associated with outcomes after radium-223. Methods: Consecutive non-trial mCRPC patients (pts) who received ≥ 1 dose of radium dichloride-223 at 4 academic and 1 community urology specific cancer centers from May 2013-June 2014 were included. Association of clinical variables (including demographics, ECOG PS, prior therapy, pain scores, PSA, alkaline phosphatase) with number of doses of radium and outcomes (including PSA, alkaline phosphatase, survival) were analyzed using chi-square statistics, cox proportional hazards, and Kaplan Meier methods. Results: In the 145 eligible pts ( 89% Caucasian, mean age 71.4 years, BMI 29.4 kg/m2,ECOG PS 0-1 in 79%),prior therapy included abiraterone (66%), enzalutamide (49%), chemotherapy (60%) and bisphosphonate/denosumab (39%). At baseline, 67% were on opiates and medi...